Showing results (201-210 of 1,831) with videos related to

Sort By:
Pageof 184
ESMO Open|July 3, 2024
A phase Ib randomized multicenter trial of isolated hepatic perfusion in combination with ipilimumab and nivolumab for uveal melanoma metastases (SCANDIUM II trial)R Olofsson Bagge, A Nelson, A Shafazand, et al.
ESMO Open|August 22, 2024
Impact of primary tumor sidedness and sex on prognosis and anti-epidermal growth factor receptor antibody efficacy in BRAF-mutant metastatic colorectal cancer: a pooled analysis of AIO studies FIRE-1, CIOX, FIRE-3, XELAVIRI, and VOLFIA H S Alig, D P Modest, S Stintzing, et al.
ESMO Open|September 4, 2024
Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with biliary tract cancerL-T Chen, A Vogel, C Hsu, et al.
ESMO Open|September 4, 2024
Adequate assessment yields appropriate care-the role of geriatric assessment and management in older adults with cancer: a position paper from the ESMO/SIOG Cancer in the Elderly Working GroupK P Loh, G Liposits, S P Arora, et al.
ESMO Open|June 7, 2024
Effectiveness of a comprehensive support program for families with parental cancer (Family-SCOUT): results of a multicenter non-randomized controlled trialA Petermann-Meyer, J P Panse, R Bremen, et al.
ESMO Open|June 7, 2024
Risk factors for early mortality from lung cancer: evolution over the last 20 years in the French nationwide KBP cohortsT C T Hoang, D Debieuvre, A-S Bravard, et al.
ESMO Open|June 4, 2024
Clinical characteristic and survival outcomes of patients with advanced NSCLC according to KRAS mutational status in the French real-life ESME cohortQ D Thomas, X Quantin, P Lemercier, et al.
ESMO Open|June 4, 2024
A phase II trial of paclitaxel plus biweekly cetuximab for patients with recurrent or metastatic head and neck cancer previously treated with both platinum-based chemotherapy and anti-PD-1 antibodyT Koyama, N Kiyota, S Boku, et al.
ESMO Open|June 4, 2024
Real-world outcomes with durvalumab after chemoradiotherapy in patients with unresectable stage III NSCLC: interim analysis of overall survival from PACIFIC-RA R Filippi, J Bar, C Chouaid, et al.
ESMO Open|June 5, 2024
A phase II study (AARDVARC) of AZD4635 in combination with durvalumab and cabazitaxel in patients with progressive, metastatic, castration-resistant prostate cancerT Alonso-Gordoa, M Goodman, C Vulsteke, et al.
Pageof 184